These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 34083988)
1. Do basal Luteinizing Hormone and Luteinizing Hormone/Follicle-Stimulating Hormone Ratio Have Significance in Prognosticating the Outcome of Singh N; Mishra N; Dogra Y J Hum Reprod Sci; 2021; 14(1):21-27. PubMed ID: 34083988 [TBL] [Abstract][Full Text] [Related]
2. Effect of basal luteinizing hormone (bLH) level on in vitro fertilization/intra-cytoplasmic injections (IVF/ICSI) outcomes in polycystic ovarian syndrome (PCOS) patients. Liu Z; Wang KH BMC Pregnancy Childbirth; 2023 Aug; 23(1):618. PubMed ID: 37644399 [TBL] [Abstract][Full Text] [Related]
3. Dose Nomogram of Individualization of the Initial Follicle-Stimulating Hormone Dosage for Patients with Polycystic Ovary Syndrome Undergoing IVF/ICSI with the GnRH-Ant Protocol: A Retrospective Cohort Study. Si M; Qi X; Zhen X; Yang C; Tian T; Long X; Qiao J Adv Ther; 2023 Sep; 40(9):3971-3985. PubMed ID: 37395872 [TBL] [Abstract][Full Text] [Related]
4. LH on GnRH-ant day to basal LH affects the IVF/ICSI outcome of PCOS women undergoing GnRH-antagonist protocol. Wei Y; Luan T; Shen J; Zhang J; Zhang J; Su Y; Ling X; Li X; Zhao C Int J Gynaecol Obstet; 2024 Feb; 164(2):624-632. PubMed ID: 37724009 [TBL] [Abstract][Full Text] [Related]
5. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Vuong TN; Phung HT; Ho MT Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882 [TBL] [Abstract][Full Text] [Related]
6. [Effect of basal serum luteinizing hormone and luteinizing hormone/follicle-stimulating hormone ratio on outcomes of in vitro fertilization-embryo transfer in patients with polycystic ovarian syndrome]. Geng X; Ou X; Liao Y; Tan W; Wang S; Quan S Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):857-60. PubMed ID: 23803197 [TBL] [Abstract][Full Text] [Related]
8. The serum follicle stimulating hormone-to-luteinizing hormone ratios can predict assisted reproductive technology outcomes in women undergoing gonadotropin releasing hormone antagonist protocol. Zhao S; Xu H; Wu X; Xia L; Li J; Zhang D; Zhang A; Xu B Front Endocrinol (Lausanne); 2023; 14():1093954. PubMed ID: 36793280 [TBL] [Abstract][Full Text] [Related]
9. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response. Xiao ZN; Peng JL; Yang J; Xu WM Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815 [TBL] [Abstract][Full Text] [Related]
10. Impact of stimulation with luteinizing hormone activity on IVF outcomes in patients with polycystic ovary syndrome. Kugelman N; Pooni A; Rotshenker-Olshinka K; Bellemare V; Digby A; Dahan MH J Turk Ger Gynecol Assoc; 2024 Jun; 25(2):60-65. PubMed ID: 38867686 [TBL] [Abstract][Full Text] [Related]
11. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels. Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817 [TBL] [Abstract][Full Text] [Related]
12. What is the best treatment for women with polycystic ovarian syndrome and high LH/FSH ratio? A comparison among in vitro fertilization with GnRH agonist, GnRH antagonist and in vitro maturation. Ganor-Paz Y; Friedler-Mashiach Y; Ghetler Y; Hershko-Klement A; Berkovitz A; Gonen O; Shulman A; Wiser A J Endocrinol Invest; 2016 Jul; 39(7):799-803. PubMed ID: 26797707 [TBL] [Abstract][Full Text] [Related]
13. The ratio of exogenous Luteinizing hormone to Follicle stimulating hormone administered for controlled ovarian stimulation is associated with oocytes' number and competence. Albu D; Albu A Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31850491 [TBL] [Abstract][Full Text] [Related]
14. Progesterone protocol versus gonadotropin-releasing hormone antagonist protocol in women with polycystic ovarian syndrome undergoing Zhu X; Ye H; Ye J; Fu Y Ann Transl Med; 2021 Mar; 9(5):387. PubMed ID: 33842608 [TBL] [Abstract][Full Text] [Related]
15. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159 [TBL] [Abstract][Full Text] [Related]
16. Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol. Huang TC; Huang MZ; Seow KM; Yang IJ; Pan SP; Chen MJ; Hwang JL; Chen SU Sci Rep; 2021 Nov; 11(1):22732. PubMed ID: 34815477 [TBL] [Abstract][Full Text] [Related]
17. Early Follicular Phase Human Chorionic Gonadotropin Addition May Improve the Outcomes of Zhang C; Wu F; Wu Z; Sun B; Chen C; Qian W Front Endocrinol (Lausanne); 2021; 12():739773. PubMed ID: 34707571 [TBL] [Abstract][Full Text] [Related]
18. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients. Hosseini MA; Aleyasin A; Saeedi H; Mahdavi A J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044 [TBL] [Abstract][Full Text] [Related]
19. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663 [TBL] [Abstract][Full Text] [Related]
20. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]